Beta Bionics, INC

Beta Bionics reported a 38% year-over-year increase in second quarter 2026 net sales to $32.0 million, driven by strong performance in the Pharmacy Benefit Plan channel, while net loss widened to $23.4 million.

Beta Bionics announces updated timeline for its Mint patch pump, now expecting full commercialization by Q2 2027, pending FDA clearance.

Beta Bionics reported a 57% year-over-year increase in first quarter 2026 net sales to $27.6 million, driven by strong performance in the Pharmacy Benefit Plan channel, and raised its full-year revenue guidance.

Beta Bionics, Inc. received a U.S. Food and Drug Administration warning letter citing deficiencies in its quality management system and reporting, though it does not expect a material impact on product commercialization.

Beta Bionics announced preliminary, unaudited fourth quarter 2025 topline financial results showing significant growth in net sales and customer base.

Beta Bionics reported strong third-quarter 2025 financial results, including a 63% increase in net sales, and subsequently raised its full-year 2025 guidance.

Beta Bionics reports a 38% increase in Q2 net sales driven by single-use product growth, but net loss also widens due to increased operating expenses.

Beta Bionics reports Q1 2026 net sales of $27.6 million, driven by growth in iLet adoption and recurring revenue from single-use products.

Beta Bionics, Inc. announced significant revenue growth and new patient adoption for its iLet Bionic Pancreas, alongside increased operating expenses and net losses, as it continues to invest heavily in commercialization and R&D.

Beta Bionics, a medical device company specializing in diabetes management, announced significant revenue and patient growth for the second quarter and first half of 2025, driven by increased adoption of its iLet Bionic Pancreas, while continuing to incur substantial net losses due to ongoing investments in commercialization and product development.

Beta Bionics reports increased revenue in Q1 2025, fueled by growing adoption of its iLet Bionic Pancreas system.

Beta Bionics, a medical device company, reported significant revenue growth and increased iLet adoption in its 2025 annual filing, despite ongoing operating losses and regulatory scrutiny.

Beta Bionics files an amendment to its 2024 annual report to correct administrative errors in executive certifications, with no changes to other financial disclosures.

Beta Bionics' 10-K filing reveals a significant increase in revenue and installed base for its iLet Bionic Pancreas in 2024, alongside ongoing research and development efforts.

Beta Bionics, Inc. (BBNX) CFO Stephen Feider amended a Form 4 filing to correct share counts related to option exercises and sales executed under a Rule 10b5-1 trading plan.

Beta Bionics, Inc. (BBNX) Chief Financial Officer, Stephen Feider, reported transactions involving the sale of company common stock and the acquisition of stock options under a pre-arranged trading plan.

Beta Bionics Chief Commercial Officer Mark Hopman sold 1,258 shares of common stock for approximately $18,875 under a pre-arranged Rule 10b5-1 trading plan.

Beta Bionics, Inc. reports that Director Christy Jones sold 1,406 shares of common stock on June 24, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Chief Commercial Officer Mark Hopman sold 275 shares of Beta Bionics common stock under a pre-arranged 10b5-1 trading plan.

Director Christy Jones sold 2,811 shares of Beta Bionics, Inc. common stock on June 4, 2026, via a Rule 10b5-1 trading plan.

Beta Bionics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect directors and ratify auditor appointment.

Beta Bionics files a registration statement to increase the number of shares offered in its public offering by 2,300,000, including an underwriter option, following the effectiveness of its initial S-1 registration.

Beta Bionics, a medical device company focused on diabetes management, is going public with an offering of 10 million shares of common stock, aiming to raise approximately $163 million to support its innovative iLet Bionic Pancreas system and future product development.

Beta Bionics, Inc., a medical device company, has filed an amendment to its S-1 registration statement with the SEC for an initial public offering, signaling its intent to commercialize its innovative iLet Bionic Pancreas, an automated insulin delivery system designed to simplify diabetes management.

Beta Bionics, a medical device company focused on diabetes management, is seeking to raise capital through an initial public offering and concurrent private placement to fund its product development and commercialization efforts.

Beta Bionics updates its bylaws, detailing stockholder meeting procedures, director responsibilities, and indemnification policies, as the company prepares for a possible initial public offering.

Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 595,000 shares, representing 1.3% of Beta Bionics, Inc.'s common stock, as of June 30, 2026.

Divisadero Street Capital Management, LP and affiliated entities report beneficial ownership of 6.9% of Beta Bionics, Inc. common stock.

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 5,945,488 shares, representing 13.4% of Beta Bionics, Inc.'s common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong report beneficial ownership of 2,000,000 shares, representing 4.5% of Beta Bionics, Inc. common stock.

Multiple entities and individuals associated with Farallon Capital Management have filed Schedule 13G amendments, collectively reporting significant beneficial ownership of Beta Bionics, Inc. common stock.

The Vanguard Group has reported zero beneficial ownership in Beta Bionics Inc. following an internal realignment.